Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions Head and Neck Cancer

Head and Neck Cancer

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

The abstract concludes: 
Transoral resection of p16+ OPC is safe and results in good oncologic outcome, presenting a promising deintensification approach. For patients with low-risk disease, 2-yr PFS is favorable without post-operative therapy. For those with uninvolved surgical margins, <5 involved nodes, and minimal (<1mm) ENE, reduced dose postoperative RT without chemotherapy appears sufficient. Transoral surgery plus 50Gy should be compared to optimal non-surgical therapy in a phase III trial. Clinical trial information: NCT01898494.
————————————————————————————————————————————————————————
 
6501 Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer.
 
Renaud Garrel, Françoise Perriard, Valentin Favier, et al.
 
The abstract concludes: 
This study demonstrated the oncological equivalence of the SN approach compared to the ND approach in a multicenter study with a lower morbidity and care consumption in the SN approach during the 6 first post-operative months. Treatment based on sentinel node biopsy is established as a standard of care in OC. Clinical trial information: NCT02855723.
————————————————————————————————————————————————————————
 
6503 Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.
 
Bhumsuk Keam, Eun Joo Kang, Myung-Ju Ahn, et al. 
 
The abstract concludes: 
In this first randomized trial in patients with recurred or metastatic ACC, axitinib significantly increased 6-month PFS rate compared to observation. Clinical trial information: NCT02859012.
————————————————————————————————————————————————————————
 
6504 Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.
 
Alan Loh Ho, Glenn J. Hanna, Catherine Rose Scholz, et al.
 
The abstract concludes: 
Encouraging activity of tipifarnib was observed in HRASm solid tumors. Clinical trial information: NCT02383927, NCT02535650.
————————————————————————————————————————————————————————
 
6505 KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
 
Kevin Joseph Harrington, Danny Rischin, Richard Greil, et al.
 
The abstract concludes: 
In patients with R/M HNSCC, longer median PFS2 was observed in the CPS ≥20 and CPS ≥1 populations for P vs E, and in the CPS ≥20, CPS ≥1, and total populations for P+C vs E. These data further support use of 1L P or P+C in patients with R/M HNSCC. Clinical trial information: NCT02358031.
————————————————————————————————————————————————————————
 
6506 Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.
 
Nandini Sharrel Menon, Vanita Noronha, Vijay Maruti Patil, Set al.
 
The abstract concludes: 
OMC improves outcomes in palliatively treated head and neck cancer and is a new standard of care in this setting, in addition to the EXTREME and KEYNOTE-048 regimen. Clinical trial information: CTRI/2015/11/006388.
————————————————————————————————————————————————————————
 
6507 TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
 
Joel Guigay, Jerome Fayette, Ricard Mesia, et al.
 
The abstract concludes: 
An improvement in the QoL of patients was observed in the TPEx arm compared to that of the EXTREME arm. Exploratory analysis showed that the taxane-based TPEx regimen followed by IO in 2nd line could provide interesting median OS for pts who need CT in 1st line, with less toxicity than EXTREME. This sequential treatment deserves to be compared to a strategy that starts with Platinum+5FU+pembrolizumab. Clinical trial information: NCT02268695.
————————————————————————————————————————————————————————
 
6508 Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.
 
Christopher Nutting, Keith Rooney, Bernadette Foran, et al.
 
The abstract concludes: 
Do-IMRT reduced RT dose to the DARS and improved patient reported swallowing function compared with S-IMRT. This is the first randomised study to demonstrate functional benefit of swallow-sparing IMRT in OPC. Clinical trial information: 25458988.
 
————————————————————————————————————————————————————————
 
Read Now a comment by Dr. Barbara Burtness:
 
————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Clinical Science Symposium
Tumor Intrinsic and Extrinsic Factors Affecting Immunotherapy Response in Head and Neck Cancer
 
Poster Discussion Session
Head and Neck Cancer
 
Poster Session
Head and Neck Cancer
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Head and Neck (Abstracts #6500, 6501, 6505)
Access Content Now